Business
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidatesIambic to receive up to $25 million through a
About this update from Revolution Medicines, Inc.
[{"type":"text","content":"Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidatesIambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines’ access to Iambic’s industry-leading NeuralPLexer model for protein structure prediction REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. In this multi-year agreement, Iambic will use structures and molecular libraries provided by Revolution Medicines to train bespoke versions of NeuralPLexer, Iambic’s industry-leading model for protein-ligand structure prediction. Revolution Medicines will also have access to Iambic’s PropANE model, a pre-trained graph neural network deployed across dozens of drug properties for lead selection and optimization. “We are impressed with the Iambic team and the potential of their platform to enable the discovery of novel compounds on behalf of Revolution Medicines' portfolio,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “The capabilities of Iambic’s AI-driven discovery platform, partnered with our unique collection of proprietary data, present an opportunity to rapidly explore oncology targets known to be challenging to address through conventional drug discovery approaches.” Iambic will build custom versions of NeuralPLexer and other technologies trained on Revolution Medicines' proprietary data to inform drug discovery against novel drug targets. Both companies will have access to the improved models, and each company retains rights to a limited number of exclusive targets as well as the ability to designate additional exclusive targets to pursue independently. “We are thrilled to work with a visionary company like Revolution Medicines on what we believe is a novel biopharma collaboration,” said Tom Miller, Ph.D.,...